Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (3386)	5/24/2003 4:22:42 AM
From: Crossy	Respond to of 37387

Joe, I was lucky to listen to it last week. The CFO is pretty forthcoming, I heard.. maybe you should give them a call.. rgrds CROSSY

To: JoeinIowa who wrote (3386)	5/24/2003 11:16:11 AM
From: Crossy	Read Replies (2) \| Respond to of 37387

re: Innovative Companies Ticker: GORX (NasdaqSC) some info rehashed from the 10K and the last CC (I hop my memory serves me well here <g>) GORX is active in 3 areas - Contract manufacturing of OTC drugs Production/Marketing of mass "distribution" products such as dietary supplements - segment called "Distribution" PBM Services (Pharmaceutical Benefit SErvices) While the company is still valued cheaply fundamentally in this area of the market with P/BK of 2, PSR of 0.65 and PE of around 10, future prospects look even better because they announced a move into a hot part of the generics segment. They already possess FDA certified production facilities (GCMP cert) and recently hired the necessary qualified personnel to file ANDAs with the FDA. The recent CC explains their steps in detail and also features the CEO talking about Able Labs (ABRX) as their role model. Because they are a "balanced portfolio" which is already generating cash nicely, the upfront expenses for a generics franchise should be more than manageable. Most of the necessary resrouces are already present inhouse. CEO promised 3 ANDAs to file until end of 2004 and seems intent to file the first, most important one later 2003. IT should be in a blockbuster drug area where patent protection will expire shortly. Shortterm, their core business should display some nice growth. Midterm their generics side may significantly add shareholder value. GORX trades at a marketcap of around $10m right now. ABRX now boasts a marketcap of more than $100m. IF GORX executes its strategy succesfully, a nice multi-bagger could be earned here.. rgrds CROSSY